Medical Ikkou Group Co Ltd

Medical Ikkou Group maintains a conservative capital structure with a debt-to-equity ratio of 0.66, below the industry median of 0.82. The company holds 6.12 billion JPY in cash and equivalents, but net cash is negative after subtracting long-term debt of 10.36 billion JPY. Free cash flow of 769 million JPY in the latest period reflects modest liquidity generation, with a current ratio of 1.65 indicating adequate short-term solvency. Profitability metrics show a return on equity of 8.16% and return on assets of 3.4%, both below the industry median of 9.2% and 4.1% respectively. Gross margin of 11.8% aligns with the cohort median, but operating margin of 3.14% lags behind the 4.5% industry average, suggesting operational inefficiencies in cost control. The company's revenue is concentrated across four segments: Dispensing Pharmacy (58% of revenue), Healthcare (21%), Medicine Wholesale (15%), and Real Estate (6%). Geographically, operations are entirely Japan-based, exposing the company to domestic regulatory and demographic risks. Revenue growth has been flat YoY, with a 0.3% decline in the latest fiscal year. Outlook for FY2024 shows a projected 1.2% revenue contraction, driven by pricing pressures in the dispensing pharmacy segment and reduced demand in nursing care facilities. Capital expenditure of -1.01 billion JPY indicates asset divestitures or write-downs. Risk assessment flags include medium liquidity risk due to negative net cash and a low dilution risk score. No recent equity issuance or ATM programs are disclosed, and the company maintains a stable share count with no dilution expected in the next 12 months. Recent 10-K filings highlight risks from Japan's aging population and potential regulatory changes in pharmacy reimbursement rates. No material litigation or earnings call transcripts were identified in the latest reporting period.